Raphael Pharmaceutical (Raphael Pharmaceutical) Equity-to-Asset : -0.29 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Raphael Pharmaceutical's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.10 Mil. Raphael Pharmaceutical's Total Assets for the quarter that ended in Mar. 2024 was $0.35 Mil.

The historical rank and industry rank for Raphael Pharmaceutical's Equity-to-Asset or its related term are showing as below:

RAPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.51 Med: -0.06 Max: 0.79
Current: -0.29

During the past 4 years, the highest Equity to Asset Ratio of Raphael Pharmaceutical was 0.79. The lowest was -0.51. And the median was -0.06.

RAPH's Equity-to-Asset is ranked worse than
91.44% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs RAPH: -0.29

Raphael Pharmaceutical Equity-to-Asset Historical Data

The historical data trend for Raphael Pharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical Equity-to-Asset Chart

Raphael Pharmaceutical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.13

0.30

0.32

0.79

Raphael Pharmaceutical Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial									-0.06	-0.51	-0.19	0.79	-0.29

Competitive Comparison of Raphael Pharmaceutical's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Raphael Pharmaceutical's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's Equity-to-Asset falls into.

Raphael Pharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Raphael Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	0.267	/	0.339
	=

Raphael Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.103	/	0.353
	=

Raphael Pharmaceutical (OTCPK:RAPH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Raphael Pharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605

Website

https://www.raphaelpharmaceutical.com

Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.

Executives

Joseph Press	director	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo	director, 10 percent owner, officer: Chief Executive Officer	4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria	director, officer: Chief Technology Officer	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya	director	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay	director	C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash	director
Guy Ofir	director, 10 percent owner, officer: President	40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen	director, 10 percent owner, officer: Secretary Treasurer Director	51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines